Trial Profile
An Open-label, Multicenter Phase Ib/2a Study of TEW-7197 (Vactosertib) Plus Weekly Paclitaxel as Second-line Treatment for Metastatic Gastric Adenocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Vactosertib (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions
- Sponsors MedPacto
- 29 Dec 2022 Results published in the Medpacto media release.
- 17 Mar 2021 Planned End Date changed from 20 Jun 2022 to 31 Dec 2022.
- 17 Mar 2021 Status changed from recruiting to active, no longer recruiting.